[Biochemical aspects of digitalis therapy].
D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors; D000818:Animals; D001001:Anura; D001711:Biotransformation; D001921:Brain / Q000201:enzymology; D002118:Calcium / Q000494:pharmacology*; D002297:Cardanolides / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D002415:Cats; D002623:Chemistry Techniques, Analytical; D003864:Depression, Chemical; D004071:Digitalis Glycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000032:analysis / Q000378:metabolism / Q000494:pharmacology* / Q000506:poisoning / Q000627:therapeutic use; D004074:Digitoxin / Q000378:metabolism / Q000494:pharmacology / Q000633:toxicity; D004285:Dogs; D004357:Drug Synergism; D006321:Heart / Q000187:drug effects*; D006331:Heart Diseases / Q000188:drug therapy*; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D008099:Liver / Q000032:analysis; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism*; D010042:Ouabain / Q000378:metabolism; D011188:Potassium / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D013268:Stimulation, Chemical; D013997:Time Factors
D002297:Cardanolides; D004071:Digitalis Glycosides; D010042:Ouabain; D004074:Digitoxin; D000251:Adenosine Triphosphatases; D011188:Potassium; D002118:Calcium
Biochemische Aspekte der Digitalistherapie.